The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), a class of injectable antidiabetic drugs, have shown significant efficacies in improving glycemic and weight control in patients with type 2 diabetes (T2D). However, the long‐term safety of GLP‐1 RAs remains insufficiently st...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley
2024-10-01
|
| Seri Bilgileri: | Journal of Diabetes |
| Konular: | |
| Online Erişim: | https://doi.org/10.1111/1753-0407.70013 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|